Serologic response to hepatitis B vaccine in HIV infected and high-risk HIV uninfected adolescents in the REACH cohort

Craig M. Wilson, Jonas H. Ellenberg, Mary K. Sawyer, Marvin Belzer, Peggy A. Crowley-Nowick, Ana Puga, Donna C. Futterman, Ligia Peralta

Research output: Contribution to journalArticle

47 Citations (Scopus)

Abstract

Purpose: To evaluate hepatitis B (HBV) vaccine response rates in HIV infected and high-risk HIV uninfected youth and examine associations with responsiveness in the HIV infected group. Methods: Cohorts within the Reaching for Excellence in Adolescent Care and Health (REACH) study population were defined based on receipt of HBV vaccine both retrospectively and prospectively. Sero-responsiveness was determined by HBsAb measurements. Testing was done for HBsAg, HBsAb, and HBcAb. For HBsAb, a value of > 10 International Units per liter was considered a positive response, and the data were collected as either positive or negative from each of the reporting laboratories. Covariates of responsiveness were explored in univariate and multivariate models for each cohort. Results: Sixty-one subjects had received a three-dose vaccination course at the time of entry into REACH. HIV uninfected subjects had significantly higher rates of response by serology compared with HIV infected subjects (70% vs. 41.1%; χ2 = .05; RR = .586, 95% CI: .36-.96). By the time of an annual visit 43 subjects had received three vaccinations with at least one occurring in the study period. The rates of response were similar for the HIV infected and uninfected groups (37.1% vs. 37.5%) in this cohort. Univariate and multivariate analysis in the prospective HIV infected group (N = 35) found an association between elevated CD8+/CD38+/HLA-DR+ T cells and lack of HBV vaccine responsiveness (6.7% vs. 60%; χ2 = .03; RR = .12, 95% CI: .02-.55). Conclusions: The poor HBV vaccine response rate in the HIV uninfected high-risk adolescents was unexpected and suggests that HBV vaccination doses have not been optimized for older adolescents. This is the first report of decreased responsiveness in HIV infected subjects being associated with elevated CD8+/CD38+/HLA-DR+ T cells and suggests that ongoing viral replication and concomitant immune system activation decreases the ability of the immune system in HIV infected subjects to respond to vaccination.

Original languageEnglish (US)
Pages (from-to)123-129
Number of pages7
JournalJournal of Adolescent Health
Volume29
Issue number3 SUPPL. 1
DOIs
StatePublished - 2001

Fingerprint

Hepatitis B Vaccines
HIV
Vaccination
Vaccines
HLA-DR Antigens
Immune System
Adolescent Health
T-Lymphocytes
Serology
Hepatitis B Surface Antigens
Multivariate Analysis

Keywords

  • Adolescents
  • HBV vaccine
  • HIV infection

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health

Cite this

Wilson, C. M., Ellenberg, J. H., Sawyer, M. K., Belzer, M., Crowley-Nowick, P. A., Puga, A., ... Peralta, L. (2001). Serologic response to hepatitis B vaccine in HIV infected and high-risk HIV uninfected adolescents in the REACH cohort. Journal of Adolescent Health, 29(3 SUPPL. 1), 123-129. https://doi.org/10.1016/S1054-139X(01)00278-6

Serologic response to hepatitis B vaccine in HIV infected and high-risk HIV uninfected adolescents in the REACH cohort. / Wilson, Craig M.; Ellenberg, Jonas H.; Sawyer, Mary K.; Belzer, Marvin; Crowley-Nowick, Peggy A.; Puga, Ana; Futterman, Donna C.; Peralta, Ligia.

In: Journal of Adolescent Health, Vol. 29, No. 3 SUPPL. 1, 2001, p. 123-129.

Research output: Contribution to journalArticle

Wilson, CM, Ellenberg, JH, Sawyer, MK, Belzer, M, Crowley-Nowick, PA, Puga, A, Futterman, DC & Peralta, L 2001, 'Serologic response to hepatitis B vaccine in HIV infected and high-risk HIV uninfected adolescents in the REACH cohort', Journal of Adolescent Health, vol. 29, no. 3 SUPPL. 1, pp. 123-129. https://doi.org/10.1016/S1054-139X(01)00278-6
Wilson, Craig M. ; Ellenberg, Jonas H. ; Sawyer, Mary K. ; Belzer, Marvin ; Crowley-Nowick, Peggy A. ; Puga, Ana ; Futterman, Donna C. ; Peralta, Ligia. / Serologic response to hepatitis B vaccine in HIV infected and high-risk HIV uninfected adolescents in the REACH cohort. In: Journal of Adolescent Health. 2001 ; Vol. 29, No. 3 SUPPL. 1. pp. 123-129.
@article{5ee880c1359e4870af889e0f10a99625,
title = "Serologic response to hepatitis B vaccine in HIV infected and high-risk HIV uninfected adolescents in the REACH cohort",
abstract = "Purpose: To evaluate hepatitis B (HBV) vaccine response rates in HIV infected and high-risk HIV uninfected youth and examine associations with responsiveness in the HIV infected group. Methods: Cohorts within the Reaching for Excellence in Adolescent Care and Health (REACH) study population were defined based on receipt of HBV vaccine both retrospectively and prospectively. Sero-responsiveness was determined by HBsAb measurements. Testing was done for HBsAg, HBsAb, and HBcAb. For HBsAb, a value of > 10 International Units per liter was considered a positive response, and the data were collected as either positive or negative from each of the reporting laboratories. Covariates of responsiveness were explored in univariate and multivariate models for each cohort. Results: Sixty-one subjects had received a three-dose vaccination course at the time of entry into REACH. HIV uninfected subjects had significantly higher rates of response by serology compared with HIV infected subjects (70{\%} vs. 41.1{\%}; χ2 = .05; RR = .586, 95{\%} CI: .36-.96). By the time of an annual visit 43 subjects had received three vaccinations with at least one occurring in the study period. The rates of response were similar for the HIV infected and uninfected groups (37.1{\%} vs. 37.5{\%}) in this cohort. Univariate and multivariate analysis in the prospective HIV infected group (N = 35) found an association between elevated CD8+/CD38+/HLA-DR+ T cells and lack of HBV vaccine responsiveness (6.7{\%} vs. 60{\%}; χ2 = .03; RR = .12, 95{\%} CI: .02-.55). Conclusions: The poor HBV vaccine response rate in the HIV uninfected high-risk adolescents was unexpected and suggests that HBV vaccination doses have not been optimized for older adolescents. This is the first report of decreased responsiveness in HIV infected subjects being associated with elevated CD8+/CD38+/HLA-DR+ T cells and suggests that ongoing viral replication and concomitant immune system activation decreases the ability of the immune system in HIV infected subjects to respond to vaccination.",
keywords = "Adolescents, HBV vaccine, HIV infection",
author = "Wilson, {Craig M.} and Ellenberg, {Jonas H.} and Sawyer, {Mary K.} and Marvin Belzer and Crowley-Nowick, {Peggy A.} and Ana Puga and Futterman, {Donna C.} and Ligia Peralta",
year = "2001",
doi = "10.1016/S1054-139X(01)00278-6",
language = "English (US)",
volume = "29",
pages = "123--129",
journal = "Journal of Adolescent Health",
issn = "1054-139X",
publisher = "Elsevier USA",
number = "3 SUPPL. 1",

}

TY - JOUR

T1 - Serologic response to hepatitis B vaccine in HIV infected and high-risk HIV uninfected adolescents in the REACH cohort

AU - Wilson, Craig M.

AU - Ellenberg, Jonas H.

AU - Sawyer, Mary K.

AU - Belzer, Marvin

AU - Crowley-Nowick, Peggy A.

AU - Puga, Ana

AU - Futterman, Donna C.

AU - Peralta, Ligia

PY - 2001

Y1 - 2001

N2 - Purpose: To evaluate hepatitis B (HBV) vaccine response rates in HIV infected and high-risk HIV uninfected youth and examine associations with responsiveness in the HIV infected group. Methods: Cohorts within the Reaching for Excellence in Adolescent Care and Health (REACH) study population were defined based on receipt of HBV vaccine both retrospectively and prospectively. Sero-responsiveness was determined by HBsAb measurements. Testing was done for HBsAg, HBsAb, and HBcAb. For HBsAb, a value of > 10 International Units per liter was considered a positive response, and the data were collected as either positive or negative from each of the reporting laboratories. Covariates of responsiveness were explored in univariate and multivariate models for each cohort. Results: Sixty-one subjects had received a three-dose vaccination course at the time of entry into REACH. HIV uninfected subjects had significantly higher rates of response by serology compared with HIV infected subjects (70% vs. 41.1%; χ2 = .05; RR = .586, 95% CI: .36-.96). By the time of an annual visit 43 subjects had received three vaccinations with at least one occurring in the study period. The rates of response were similar for the HIV infected and uninfected groups (37.1% vs. 37.5%) in this cohort. Univariate and multivariate analysis in the prospective HIV infected group (N = 35) found an association between elevated CD8+/CD38+/HLA-DR+ T cells and lack of HBV vaccine responsiveness (6.7% vs. 60%; χ2 = .03; RR = .12, 95% CI: .02-.55). Conclusions: The poor HBV vaccine response rate in the HIV uninfected high-risk adolescents was unexpected and suggests that HBV vaccination doses have not been optimized for older adolescents. This is the first report of decreased responsiveness in HIV infected subjects being associated with elevated CD8+/CD38+/HLA-DR+ T cells and suggests that ongoing viral replication and concomitant immune system activation decreases the ability of the immune system in HIV infected subjects to respond to vaccination.

AB - Purpose: To evaluate hepatitis B (HBV) vaccine response rates in HIV infected and high-risk HIV uninfected youth and examine associations with responsiveness in the HIV infected group. Methods: Cohorts within the Reaching for Excellence in Adolescent Care and Health (REACH) study population were defined based on receipt of HBV vaccine both retrospectively and prospectively. Sero-responsiveness was determined by HBsAb measurements. Testing was done for HBsAg, HBsAb, and HBcAb. For HBsAb, a value of > 10 International Units per liter was considered a positive response, and the data were collected as either positive or negative from each of the reporting laboratories. Covariates of responsiveness were explored in univariate and multivariate models for each cohort. Results: Sixty-one subjects had received a three-dose vaccination course at the time of entry into REACH. HIV uninfected subjects had significantly higher rates of response by serology compared with HIV infected subjects (70% vs. 41.1%; χ2 = .05; RR = .586, 95% CI: .36-.96). By the time of an annual visit 43 subjects had received three vaccinations with at least one occurring in the study period. The rates of response were similar for the HIV infected and uninfected groups (37.1% vs. 37.5%) in this cohort. Univariate and multivariate analysis in the prospective HIV infected group (N = 35) found an association between elevated CD8+/CD38+/HLA-DR+ T cells and lack of HBV vaccine responsiveness (6.7% vs. 60%; χ2 = .03; RR = .12, 95% CI: .02-.55). Conclusions: The poor HBV vaccine response rate in the HIV uninfected high-risk adolescents was unexpected and suggests that HBV vaccination doses have not been optimized for older adolescents. This is the first report of decreased responsiveness in HIV infected subjects being associated with elevated CD8+/CD38+/HLA-DR+ T cells and suggests that ongoing viral replication and concomitant immune system activation decreases the ability of the immune system in HIV infected subjects to respond to vaccination.

KW - Adolescents

KW - HBV vaccine

KW - HIV infection

UR - http://www.scopus.com/inward/record.url?scp=0034870146&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034870146&partnerID=8YFLogxK

U2 - 10.1016/S1054-139X(01)00278-6

DO - 10.1016/S1054-139X(01)00278-6

M3 - Article

VL - 29

SP - 123

EP - 129

JO - Journal of Adolescent Health

JF - Journal of Adolescent Health

SN - 1054-139X

IS - 3 SUPPL. 1

ER -